Inicio > BIGG > Resultado de la búsqueda

    Resultados: 3

    Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) for Use of Serogroup B Meningococcal (MenB) Vaccines in Adolescents and Young Adults (Including College Students)

    MMWR recomm. rep; 64 (41), 2015
    Two serogroup B meningococcal (MenB) vaccines have recently been licensed for use in the U.S. (MenB-FHbp [Trumenba, Wyeth Pharmaceuticals, Inc.] and MenB-4C [Bexsero, Novartis Vaccines]). Both vaccines were approved for use in persons aged 10 through 25 years. MenB-FHbp was licensed as a three-dose serie...
    Vacunas Meningococicas/uso terapéutico, Infecciones Meningocócicas/inmunología, Neisseria meningitidis Serogrupo B/inmunología
    Texto completo

    Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) for Use of Serogroup B Meningococcal (MenB) Vaccines in Persons at Increased Risk for Serogroup B Meningococcal Disease

    MMWR recomm. rep; 64 (22), 2015
    In October 2014, the Food and Drug Administration (FDA) licensed the first serogroup B meningococcal (MenB) vaccine (MenB-FHbp [Trumenba®, Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer Inc., Philadelphia, Pennsylvania]) as a 3-dose series. The FDA licensed a second MenB vaccine (MenB-4C [Bexsero®...
    Vacunas Meningococicas/uso terapéutico, Infecciones Meningocócicas/inmunología, Programas de Inmunización
    Texto completo

    Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) for Infant Meningococcal Vaccines

    MMWR recomm. rep; 62 (RR02), 2013
    Two meningococcal vaccines, MenACWY-D and Hib-MenCY-TT, were licensed for use in infants in April 2011 and June 2012, respectively. Evidence of benefits, harms, values and preferences, and cost-effectiveness were reviewed in accordance with GRADE methods[1]. The primary policy question was “Should men...
    Infecciones Meningocócicas/prevención & control, Vacunas Meningococicas/uso terapéutico, Vacunas Meningococicas/efectos adversos
    Texto completo